Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11398
Title: Long-term outcomes of calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.
Authors: Mackay, A J;Angus, Peter W;Gow, Paul J
Affiliation: Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Dec-2011
Citation: Transplantation Proceedings; 43(10): 3802-6
Abstract: It has become common practice to withdraw or reduce calcineurin inhibitors (CNI) in patients with renal dysfunction after liver transplantation; however, little is known about the long-term outcome of this strategy. This study investigates the long-term results of CNI withdrawal for post-liver transplant renal dysfunction and examines for factors that predict a significant improvement in renal function.A retrospective database review was performed to examine outcomes in patients with CNI withdrawn for chronic renal impairment. Univariate analyses were used to identify predictors of an improvement in creatinine clearance (CrC).Sixty patients (44 males) were included. Of these, 82% of patients were switched to mycophenolate mofetil and 18% azathioprine. Median follow-up after CNI withdrawal was 48 (range 3-72) months. Postwithdrawal, there was an initial improvement in CrCl (mean 5.5 mL), which remained above baseline levels at 6 years. Acute cellular rejection developed in six patients (10%), but there was no rejection-associated graft loss. A shorter time from transplantation to conversion was associated with greatest improvement in CrCI.CNI withdrawal is associated with a significant initial improvement and then arrest in long-term decline of renal function. Rejection in this setting is uncommon. The greatest benefit is seen in patients switched within the early years after transplantation.
Internal ID Number: 22172850
URI: http://ahro.austin.org.au/austinjspui/handle/1/11398
DOI: 10.1016/j.transproceed.2011.10.044
URL: http://www.ncbi.nlm.nih.gov/pubmed/22172850
Type: Journal Article
Subjects: Aged
Biological Markers.metabolism
Calcineurin Inhibitors
Chronic Disease
Creatinine.metabolism
Drug Substitution
Female
Graft Rejection.immunology.prevention & control
Humans
Immunosuppressive Agents.adverse effects
Kidney.drug effects.metabolism.physiopathology
Kidney Diseases.diagnosis.etiology.metabolism.physiopathology
Liver Transplantation.adverse effects.immunology
Male
Middle Aged
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Victoria
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.